Table 4.

Clinical cure rates at test-of-cure visit

Study population	No. cured with indicated drug/no. tested (%)		Difference (95% CI)
	TD-1792	Vancomycin
All-treated	79/98 (80.6)	82/99 (82.8)	−2.2 (−13.0, 8.6)
Modified all-treated	62/76 (81.6)	63/76 (82.9)	−1.3 (−13.5, 10.8)
Clinically evaluable	77/84 (91.7)	78/86 (90.7)	1.0 (−7.9, 9.7)
Microbiologically evaluable	58/63 (92.1)	58/63 (92.1)	0.0 (−10.0, 10.0)
Microbiologically evaluable patients infected with MRSA	36/38 (94.7)	34/37 (91.9)	2.8 (−9.8, 15.3)